ArticleCureus2025
Long-Term Outcomes of Neurosurgical Treatment in Glioblastoma Multiforme.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the long-term outcomes of neurosurgical treatment in glioblastoma multiforme (GBM) patients, focusing on the impact of surgical resection type, O6-methylguanine-DNA methyltransferase (MGMT) methylation status, and Karnofsky Performance Status (KPS) on survival. METHODOLOGY: A retrospective analysis was conducted on 100 GBM patients treated at Mardan Medical Complex, Mardan, Pakistan, between September 2018 and January 2025. The cohort was divided into two groups: long-term survivors (n=50) and short-term survivors (n=50). The study analyzed surgical resection type (gross total resection (GTR), subtotal resection (STR), biopsy), MGMT methylation status, and KPS scores, comparing their associations with survival outcomes.
resultsResults revealed that 56% of patients who underwent GTR survived beyond three years, compared to 24% for STR and 18% for biopsy (p<0.001). Additionally, 48% of patients with MGMT methylation survived long-term, compared to only 12% of those without methylation (p<0.001). A higher KPS score (≥70) was also significantly associated with better survival outcomes (p<0.001). The hazard ratio for GTR vs. STR was 2.5, and for MGMT methylation, it was 3.0.
conclusionIn conclusion, GTR, MGMT methylation, and a higher KPS score were significant predictors of long-term survival in GBM patients. This study provides valuable insights for optimizing treatment strategies and improving patient outcomes. Future research should focus on larger cohorts and additional genetic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.